Your partner for safety, compliance, and scientific evaluation of endocrine disruptors
Since 2018, the evaluation of endocrine disruption (ED) potential has been a mandatory regulatory requirement for plant protection and biocidal products. In 2023, new hazard classes for ED were introduced under CLP (Regulation (EC) No 1272/2008). Further regulatory requirements are also expected in cosmetic, REACH, and pharmaceutical regulations.
Our experts support you in anticipating these regulatory changes and ensuring the compliance of your substances and products across multiple markets.
Key Services for Endocrine Disruptors
Critical review of existing data:
-
Review of existing regulatory data
-
Targeted bibliographic search according to ECHA-EFSA guidance
-
Analysis of Toxcast data using our internal digital tool
Data generation and tailored testing
-
Tailored testing strategies aligned with OECD guidelines or most recognised protocols
-
Monitoring and interpretation of ED-specific studies (in vitro / in vivo)
-
In silico predictions and (Q)SAR screening
Documentation & regulatory dossiers
-
Preparation of ED-relevant sections for PPP and BPR
-
Use of regulatory compliant formats (IUCLID, EFSA table…)
-
Comprehensive documentation for internal strategic purpose or for regulatory submissions
Expert statements & defence
-
Independent scientific evaluation of ED properties and CLP classification
-
Support during regulatory interactions with authorities
-
Position papers defending ED assessment and classification